je.st
news
Eli Lilly changes outcome goals in Alzheimer's drug study
2016-03-15 22:32:15| Biotech - Topix.net
" Eli Lilly says it's changed the outcome goals for a late-stage patient study of its closely watched experimental drug for Alzheimer's disease, solanezumab. The Expedition3 trial had two primary outcome measures: changes in participants' cognition and their daily function.
Tags: study
drug
goals
outcome
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|